Biomarkers Evaluated for Lung Disease Severity in Cystic Fibrosis
|
By LabMedica International staff writers Posted on 22 Jun 2020 |

Image: The single gene, Cystic Fibrosis Transmembrane Regulator (CFTR) gene is located on the long arm of chromosome 7, and its mutations cause CF (Photo courtesy of Daryl Isaac).
Cystic fibrosis (CF) is one of the most common life-shortening monogenic disorders amongst European-derived populations currently affecting more than 85,000 patients worldwide. The diagnosis of CF is based on consensus clinical and laboratory criteria.
To confirm a diagnosis of CF, it is necessary to obtain evidence of CF transmembrane conductance regulator (CFTR) dysfunction through the identification of two CFTR gene mutations in trans previously assigned as CF disease causing, and to perform tests showing high chloride concentration in sweat, distinctive transepithelial nasal potential difference (NPD) measurements and/or assessment of CFTR (dys)function in native colonic epithelia ex vivo.
An international team of medical laboratory scientists led by the University of Debrecen (Debrecen, Hungary) have reviewed the methods used to diagnose CF. Monitoring of pulmonary inflammation via peripheral blood biomarkers is the most common strategy that could be analytically standardized and is generally reproducible. The team summarized the utility of thus far studied blood-, sputum- and bronchoalveolar lavage (BAL)-based biomarkers to evaluate inflammatory conditions in the lung and to follow treatment efficacy in CF.
Serum or plasma C-reactive protein (CRP) concentrations as indicators of systemic inflammation in CF have been analyzed and found to be increased in CF. Higher baseline plasma CRP levels (≥5.2 mg/L) were found in adult CF patients who had a more severe disease and were at higher risk for pulmonary exacerbation (PEx). Similarly, serum CRP was among those individual biomarkers, which could effectively differentiate CF children for lung disease severity.
Airway disease is characterized by chronic infection and recurrent inflammation with neutrophil dominance in association with increased production of a number of pro-inflammatory cytokines, such as IL-6, IL-8 and tumor necrosis factor-α (TNF-α). Serum IL-6 separated CF subjects from normal individuals and showed a significant reduction during antibiotic therapy. Similarly, plasma IL-8 monitored antibiotic efficacy by 21 days and indicated the onset of early re-exacerbation. Higher plasma IL-6 and IL-8 concentrations at the time of exacerbation were associated with an increased risk for being a non-responder to antibiotics.
Activated neutrophils produce several proteins under inflammatory conditions, such as NE, myeloperoxidase (MPO), calprotectin, YKL-40, etc., which circulate at a high quantity in CF blood specimens. NE is a ‘destructive’ serine protease impacting extracellular matrix proteins that forms complexes with anti-proteases leading to neutrophil elastase-antiprotease complex (NE-APC). Plasma NE-APC was elevated in persons with CF versus non-CF controls. The effect of repeated antibiotic therapy was significant on serum MPO levels and was thus utilized in assessing therapeutic efficacy in PEx. Recent discovery of new protein (e.g. human epididymis protein) and RNA-based biomarkers, such as microRNAs may offer a higher efficacy, which in aggregate may be valuable to evaluate disease prognosis and to substantiate CF drug efficacy.
The authors concluded that the field of biomarker development is rapidly evolving whereby it is expected that various omics technologies will be utilized together with advanced bioinformatics algorithms in order to grasp the multisystem complexity of CF disease in various stages of its development. The study was published online on May 16, 2020 in the journal Clinica Chimica Acta.
Related Links:
University of Debrecen
To confirm a diagnosis of CF, it is necessary to obtain evidence of CF transmembrane conductance regulator (CFTR) dysfunction through the identification of two CFTR gene mutations in trans previously assigned as CF disease causing, and to perform tests showing high chloride concentration in sweat, distinctive transepithelial nasal potential difference (NPD) measurements and/or assessment of CFTR (dys)function in native colonic epithelia ex vivo.
An international team of medical laboratory scientists led by the University of Debrecen (Debrecen, Hungary) have reviewed the methods used to diagnose CF. Monitoring of pulmonary inflammation via peripheral blood biomarkers is the most common strategy that could be analytically standardized and is generally reproducible. The team summarized the utility of thus far studied blood-, sputum- and bronchoalveolar lavage (BAL)-based biomarkers to evaluate inflammatory conditions in the lung and to follow treatment efficacy in CF.
Serum or plasma C-reactive protein (CRP) concentrations as indicators of systemic inflammation in CF have been analyzed and found to be increased in CF. Higher baseline plasma CRP levels (≥5.2 mg/L) were found in adult CF patients who had a more severe disease and were at higher risk for pulmonary exacerbation (PEx). Similarly, serum CRP was among those individual biomarkers, which could effectively differentiate CF children for lung disease severity.
Airway disease is characterized by chronic infection and recurrent inflammation with neutrophil dominance in association with increased production of a number of pro-inflammatory cytokines, such as IL-6, IL-8 and tumor necrosis factor-α (TNF-α). Serum IL-6 separated CF subjects from normal individuals and showed a significant reduction during antibiotic therapy. Similarly, plasma IL-8 monitored antibiotic efficacy by 21 days and indicated the onset of early re-exacerbation. Higher plasma IL-6 and IL-8 concentrations at the time of exacerbation were associated with an increased risk for being a non-responder to antibiotics.
Activated neutrophils produce several proteins under inflammatory conditions, such as NE, myeloperoxidase (MPO), calprotectin, YKL-40, etc., which circulate at a high quantity in CF blood specimens. NE is a ‘destructive’ serine protease impacting extracellular matrix proteins that forms complexes with anti-proteases leading to neutrophil elastase-antiprotease complex (NE-APC). Plasma NE-APC was elevated in persons with CF versus non-CF controls. The effect of repeated antibiotic therapy was significant on serum MPO levels and was thus utilized in assessing therapeutic efficacy in PEx. Recent discovery of new protein (e.g. human epididymis protein) and RNA-based biomarkers, such as microRNAs may offer a higher efficacy, which in aggregate may be valuable to evaluate disease prognosis and to substantiate CF drug efficacy.
The authors concluded that the field of biomarker development is rapidly evolving whereby it is expected that various omics technologies will be utilized together with advanced bioinformatics algorithms in order to grasp the multisystem complexity of CF disease in various stages of its development. The study was published online on May 16, 2020 in the journal Clinica Chimica Acta.
Related Links:
University of Debrecen
Latest Clinical Chem. News
- AI and Nanotechnology Enable Five-Minute Urine Drug Screening
- Study Questions Uniform Stool-Test Cutoff Across Age Groups
- Study Supports Review of Long-Term Blood-Monitoring Guidelines for Clozapine
- Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research
- Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk
- FDA Authorization Adds Gabapentin Testing to Roche Mass Spectrometry Solution
- Skin Swab Research Identifies Metabolic Changes Linked to Parkinson’s Disease
- AI Predicts Kidney Stone Composition From Routine Urine Tests
- Updated PSA Testing Guidelines Support Early Prostate Cancer Detection
- Antibody-Free Blood Test Detects Rheumatic Heart Disease Biomarker
- Blood and Spinal Fluid Biomarker May Help Track Early Huntington’s Disease
- New Biomarker Offers Longer Detection Window for Suspected GHB Exposure
- Study Finds Urine Biomarker Score Improves Five-Year Cancer Risk Prediction
- Flow Cytometry Tests Receive FDA Clearance for B-Cell Lymphoma Diagnosis
- Blood Protein Signatures May Predict Brain Vessel Damage and Cognitive Decline
- Combined Blood and Imaging Data Help Identify More Lung Cancer Cases
Channels
Molecular Diagnostics
view channel
Blood RNA Patterns Linked to CAR T-Cell Response and Survival in Lymphoma
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, which involves engineering a patient’s own immune cells to recognize and attack cancer cells, has transformed treatment for large B-cell lymphoma,... Read moreGenome Sequencing Provides Clues to Unexplained Recurrent Miscarriages
Recurrent pregnancy loss, defined as two or more miscarriages, affects about 5% of couples. In many cases, routine evaluation does not identify a cause, particularly when pregnancies have a normal chromosome... Read moreHematology
view channel
Werfen Gains FDA Clearance for ROTEM sigma Cartridge Use in Trauma
Traumatic injuries account for approximately 10% of deaths worldwide, with uncontrolled bleeding remaining a leading cause of potentially preventable trauma-related death. Trauma-induced coagulopathy further... Read more
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read moreImmunology
view channel
Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice
Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read moreMicrobiology
view channel
WHO Survey Reveals Gaps in Antimicrobial Resistance Testing and Response
Antimicrobial resistance (AMR) remains a major challenge for health systems, limiting effective treatment options for drug-resistant infections. These infections caused more than 1 million deaths and contributed... Read more
Direct-From-Specimen Pneumonia Test Detects Pathogens and Resistance in Hours
Pneumonia is a leading cause of sepsis and is associated with high mortality. Conventional culture-based pathogen identification and antimicrobial susceptibility testing can take two to four days, delaying... Read morePathology
view channel
Researchers Evaluate Automated Tissue Analysis Across Four Cancer Types
Histopathology image analysis plays a central role in cancer diagnosis, but tumor tissue can vary considerably across different regions of the same specimen. Pathologists examine cellular morphology, nuclear... Read more
AI Prostate Cancer Test Added to NCCN Guidelines for Post-Surgery Recurrence
Following radical prostatectomy, an estimated 20% to 40% of prostate cancer patients develop biochemical recurrence, marked by rising prostate-specific antigen levels that may indicate cancer recurrence.... Read more
New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read moreTechnology
view channel
Experimental Blood Test Detects Markers of Three Cancers and Alzheimer’s Disease
Colorectal cancer, glioblastoma, pancreatic cancer, and Alzheimer’s disease are serious conditions in which earlier detection may improve clinical outcomes. Blood-based testing could help identify dis... Read more
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read moreIndustry
view channel
Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil
Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more







